Lion TCR has forged a strategic partnership with the National University of Singapore Guangzhou Research Translation and Innovation Institute (NUSGRTII) to jointly drive cutting-edge innovation in cell therapy, biomedical research and interdisciplinary AI.
 
Through this synergistic collaboration, Lion TCR will harness complementary strengths to establish a robust "industry-academia-research-application" ecosystem. By consolidating resources from government, industry, and academia, aiming to accelerate industrial upgrading, facilitate technology transfer, and propel breakthrough innovations.
 
Lion TCR, is planning to combine clinical expertise in mRNA-based TCR T cell immunotherapies with NUS' world-class research capabilities. Leveraging its expertise in cell immunotherapy and AI-enabled target discovery, the firm will collaborate with NUS Guangzhou Institute on R&D innovations in biomedicine as well as interdisciplinary AI fields.

Harnessing AI to uncover novel therapeutic targets holds promise to accelerate the drug development process. This synergy is expected to catalyze mission to develop potentially curative cell therapies for cancer patients. The partnership encompasses multiple fronts - professional talent development, technology commercialization, and joint research projects at the frontiers of biomedical science and engineering. Dedicated teams from both partners will coordinate efforts, sharing resources and proprietary knowhow.